EF
CARM

Empowered Funds’s Carisma Therapeutics CARM Stock Holding History

Empowered Funds’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-30,988
Closed -$1.33K – 2116
2025
Q4 		$1.33K Hold
30,988
– – ﹤0.01% 994
2025
Q3 		$8.49K Hold
30,988
– – ﹤0.01% 1814
2025
Q2 		$12.1K Hold
30,988
– – ﹤0.01% 1745
2025
Q1 		$9.61K Hold
30,988
– – ﹤0.01% 1613
2024
Q4 		$13K Buy
30,988
+550
+2% +$453 ﹤0.01% 1652
2024
Q3 		$29.9K Buy
30,438
+1,474
+5% +$1.6K ﹤0.01% 1387
2024
Q2 		$44K Buy
28,964
+1,980
+7% +$2.95K ﹤0.01% 1360
2024
Q1 		$61.3K Sell
26,984
-21,150
-44% -$50.8K ﹤0.01% 1357
2023
Q4 		$141K Buy
48,134
+4,224
+10% +$12.6K ﹤0.01% 1231
2023
Q3 		$186K Buy
43,910
+3,476
+9% +$22K 0.01% 1162
2023
Q2 		$355K Buy
+40,434
New +$220K 0.01% 911

Other funds holding CARM

MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
UBP
Union Bancaire Privee Geneva 1, Switzerland $9.16B AUM 31.4% 1-Year Est. Return
GSEP
Golden State Equity Partners South Coast Metro, California $37.1M AUM 20.75% 1-Year Est. Return

Empowered Funds's CARM Position: Q1 2026 in Review

Empowered Funds sold out of Carisma Therapeutics (CARM) in Q1 2026, closing a stake of 30,988 shares — an estimated $1.33K sold.

Empowered Funds first reported a position in CARM in Q2 2023 and held it in 11 quarters. The position peaked at $355K in Q2 2023. 3 funds tracked by Wall St. Rank hold CARM as of Q1 2026.

  • Empowered Funds reported no remaining Carisma Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Empowered Funds sold 30,988 Carisma Therapeutics shares in Q1 2026, an estimated $1.33K.
  • Empowered Funds first reported a position in Carisma Therapeutics in Q2 2023 and held it in 11 quarters.
  • Empowered Funds's Carisma Therapeutics position peaked at $355K in Q2 2023.
  • 3 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q1 2026.

Based on Empowered Funds's 13F filing for Q1 2026, filed 15 May 2026.